Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Monashee Investment […]
Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 9,300,000 shares, a decline of 7.6% from the January 15th total of 10,070,000 shares. Based on an average trading volume of 1,710,000 shares, […]
CymaBay Therapeutics (NASDAQ:CBAY) Downgraded by Lifesci Capital to "Market Perform" themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
William Blair cut shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat.com reports. William Blair also issued estimates for CymaBay Therapeutics’ FY2026 earnings at ($0.85) EPS. A number of other brokerages have also issued reports on CBAY. Lifesci Capital reaffirmed […]